Farmos-yhtyma Oy

Orion Corporation

Farmos Group Ltd.

Orion-yhtyma Oy

Other

Hormos Medical Oy Ltd.

Risto Arvo Sakari Lammintausta

Farmos-yhtyma Oy (farmos Group Ltd.)

Arto J Karjalainen

Kauko O Kurkela

Raimo E Virtanen

Lauri V Kangas

Risto A Lammintausta

Arja Marketta Kalapudas

Arja L Karjalainen

Reino O Pelkonen

Arja Karjalainen

Paavo Huhtala

Jarmo Sakari Salonen

Reijo J Toivola

Guillermo L Blanco

Marja-Liisa Sodervall

Antti Haapalinna

Seppo Parhi

Marja-Liisa Soderwall

Pentti T Nore

Jouko Levijoki

Maire Eloranta

Eija Tiainen

Jari Ratilainen

Piero Pollesello

Juha-Matti Savola

Sirpa Rasku

Siegfried Wurster

Jukka Tenhunen

Aire Maria Laine

Leena Otsomaa

Tuula Koskelainen

Jyrki Lehtim&auml;ki

Victor Cockcroft

Hannu K Sundquist

Maarit Hillil&auml;

Raimo Saxlund

Jarmo J Pystynen

Heimo O Haikala

Arto Olavi Urtti

Olli Törmäkangas

Harry Gosta Jalonen

David Din Belle

Juha Kaivola

Carola Tilgmann

Kalervo Väänänen

Arto Tolvanen

Kari L&ouml;nnberg

Jukka Sallinen

Petri Kaheinen

Maire M Eloranta

Pirkko Härkönen

Ewen MacDonald

Antti T Vaha-Vahe

Ismo Ulmanen

Reija Jokela

Eino J Savolainen

Pekka Kotovuori

Thomas Yorio

Marja-Liisa Södervall

Matti A Lahde

Antti S Haapalinna

Hannu T Sipila

Maria-Liisa Sodervall

Aire Marja Laine

Hannu K Sunduiqst

Outi M Vainio-Kivinen

Ewen Macdonald

Raimo Virtanen

Arto Urtti

A method of isolating detomidine (I) hydrochloride as a crystalline salt is provided. The method comprises hydrogenating in the presence of a catalyst of compound of formula (II) in aqueous solution comprising hydrochloric acid, concentrating the solution by distillation, optionally adding hydrochloric acid to the concentrated solution, cooling the concentrated solution and recovering the crystallized detomidine hydrochloride. The product can be recovered directly from aqueous solution with 

Detomidine hydrochloride crystallization method

A method of isolating atipamezole hydrocloride as a crystalline salt is provided.

Atipamezole hydrochloride crystallization method

Polycyclic compounds as potent alpha2-adrenoceptor antagonists

Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na/Caexchange mechanism.

Pyridine derivatives useful for inhibiting sodium/calcium exchange system

Therapeutically active compounds of formula (I): wherein the variables shown in formula (I) are defined in the disclosure; and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of the Na/Caexchange mechanism.

[object Object]

The invention provides novel selective estrogen receptor modulator compounds of the general formula:wherein R1 and R2, which are the same or different are

Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Imidazole derivatives having affinity for &agr;2 receptors

Imidazole derivatives

Polycyclic indanylimidazoles with alpha2 adrenergic activity

Imidazole derivatives having affinity for alpha2 receptors

A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca,-ATPase are also described.

Phospholamban inhibitors and a method for increasing coronary flow

##STR1## New compounds of formula (I) wherein R.sub.1 is H, CH.sub.3, OCH.sub.3, NO.sub.2, NH.sub.2, CN, CF.sub.3, CHF.sub.2, CH.sub.2 F or halogen, R.sub.2 is a heterocyclyl radical selected from 1-imidazolyl, triazolyl, tetrazolyl, pyrazolyl, pyrimidinyl, oxazolyl, thiazolyl, isoxazolyl and isothiazolyl, R.sub.3 is H or OH, R.sub.4 is H, R.sub.5 is H or OH; or R.sub.4 is H and R.sub.3 and R.sub.5 combined form a bond; or R.sub.3 is H and R.sub.4 and R.sub.5 combined form .dbd.O; R.sub.6 is methylene, ethylene, --CHOH--, --CH.sub.2 --CHOH--, --CHOH--CH.sub.2 --, --CH.dbd.CH-- or --C(.dbd.O)--; or R.sub.4 is H and R.sub.5 and R.sub.6 combined is .dbd.CH-- or .dbd.CH--CH.sub.2 --; stereoisomers thereof and non-toxic pharmaceutically acceptable acid addition salts thereof exhibit selective aromatase inhibiting properties, compared with their desmolase inhibiting properties. The compounds of the invention are valuable in the treatment of estrogen dependent diseases, e.g. breast cancer or benign prostatic hyperplasia (BPH).

Selective aromatase inhibiting compounds

Selective aromatase inhibiting 4(5)-imidazoles

4(5) substituted imidazoles and their preparation and use

Growing community of inventors

Oulu, Finland

Arto J Karjalainen